AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7999653 — intervention group
Group type: COMPARATOR
Intervention: L + S group (n = 26) - 38 mL of 1.5% lidocaine with 1:200,000 epinephrine and 2 mL of normal saline
Number of subjects: 53
Study 31650255 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised cognitive training (CCT)
Number of subjects: 12
Study 31650255 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific CCT
Number of subjects: 12
Study 31650255 — intervention group
Group type: EXPERIMENTAL
Intervention: CCT on SCD
Number of subjects: 12
Study 29945780 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg + 10 g Cr monohydrate (n = 10)
Number of subjects: 19
Study 29945780 — intervention group
Group type: COMPARATOR
Intervention: Placebo (atorvastatin 80 mg + PL, n = 9)
Number of subjects: 19
Study 29945780 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 19
Study 27296201 — intervention group
Group type: EXPERIMENTAL
Intervention: CoreValve transcatheter aortic valve replacement
Number of subjects: 156
Study 25066668 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 0
Study 25066668 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 0
Study 23739042 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSO-524™
Number of subjects: 0
Study 23739042 — intervention group
Group type: COMPARATOR
Intervention: Fish oil
Number of subjects: 0
Study 20613461 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir (ATV)
Number of subjects: 515
Study 20613461 — intervention group
Group type: COMPARATOR
Intervention: Atazanavir/ritonavir (ATV/r)
Number of subjects: 515
Study 20613461 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 515
Study 19205870 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV biofeedback and breathing retraining
Number of subjects: 29
Study 19205870 — intervention group
Group type: COMPARATOR
Intervention: Quasi‐false alpha‐theta biofeedback
Number of subjects: 29
Study 17090333 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery with progressive muscle relaxation
Number of subjects: 22
Study 17090333 — intervention group
Group type: COMPARATOR
Intervention: Breathing exercises alone
Number of subjects: 22
Study 15360809 — intervention group
Group type: EXPERIMENTAL
Intervention: FastTrack e-mail intervention
Number of subjects: 276
Study 15360809 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 276
Study 11230288 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelium-dependent vasodilatation with acetylcholine (0.15, 0.45, 1.5, 4.5, and 15 microg. 100 mL(‐1). min(‐1))
Number of subjects: 142
Study 11230288 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelium-independent vasodilatation with sodium nitroprusside (1, 2, and 4 microg. 100 mL(‐1). min(‐1))
Number of subjects: 142
Study 9225641 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive with 20 micrograms ethinyl estradiol (EE)
Number of subjects: 5000
Study 9225641 — intervention group
Group type: COMPARATOR
Intervention: Combined oral contraceptive with 30 micrograms ethinyl estradiol (EE)
Number of subjects: 5000
Study 7968419 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic (IK) strength training program
Number of subjects: 18
Study 7968419 — intervention group
Group type: COMPARATOR
Intervention: Nonisokinetic (NIK) strength training program
Number of subjects: 18
Study 2889391 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal nitroglycerine 0.75 mg
Number of subjects: 40
Study 2889391 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution of saline (Control)
Number of subjects: 40
Study 29704183 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralized collaborative care model
Number of subjects: 666
Study 29704183 — intervention group
Group type: COMPARATOR
Intervention: Existing collaborative care model
Number of subjects: 666
Study 27852230 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 16 mg IV preoperatively
Number of subjects: 99
Study 27852230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 24126567 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-280778 single doses of 2, 5, 15, or 40 mg
Number of subjects: 0
Study 24126567 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-280778 single dose of 40 mg
Number of subjects: 0
Study 24126567 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-280778 once-daily doses of 5 or 15 mg for 7 days
Number of subjects: 0
Study 24126567 — intervention group
Group type: COMPARATOR
Intervention: Food intake
Number of subjects: 0
Study 24126567 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-280778
Number of subjects: 0
Study 23965227 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aids (DAs) for coronary prevention and diabetes medications
Number of subjects: 0
Study 23965227 — intervention group
Group type: EXPERIMENTAL
Intervention: In-clinic approach for recruitment
Number of subjects: 0
Study 23965227 — intervention group
Group type: EXPERIMENTAL
Intervention: Working closely with the practice
Number of subjects: 0
Study 20627902 — intervention group
Group type: EXPERIMENTAL
Intervention: Stemless poly‐L/D‐lactide copolymer 96 : 4 (PLDLA) implant
Number of subjects: 52
Study 20627902 — intervention group
Group type: COMPARATOR
Intervention: Swanson silicone implant
Number of subjects: 52
Study 18311686 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid tryptophan depletion (RTD)
Number of subjects: 22
Study 18311686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 15843118 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Relationships intervention
Number of subjects: 81
Study 15843118 — intervention group
Group type: COMPARATOR
Intervention: health maintenance control condition
Number of subjects: 81
Study 12750879 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate alone
Number of subjects: 40
Study 12750879 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate and fluoride
Number of subjects: 40
Study 10531155 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (500 microg)
Number of subjects: 28
Study 10531155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 8905360 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 0.2 mg incrementally after procedure
Number of subjects: 0
Study 8905360 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 0
Study 2069240 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency positive pressure ventilation (HFPPV group)
Number of subjects: 42
Study 2069240 — intervention group
Group type: COMPARATOR
Intervention: One-lung ventilation (OLV group)
Number of subjects: 42
Study 6311692 — intervention group
Group type: EXPERIMENTAL
Intervention: cimetidine 400 mg bd
Number of subjects: 12
Study 6311692 — intervention group
Group type: EXPERIMENTAL
Intervention: cimetidine 300 mg nocte
Number of subjects: 12
Study 6311692 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 150 mg bd
Number of subjects: 12
Study 6311692 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg nocte
Number of subjects: 12
Study 6311692 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 6311692 — intervention group
Group type: EXPERIMENTAL
Intervention: twice daily ranitidine
Number of subjects: 12
Study 6311692 — intervention group
Group type: EXPERIMENTAL
Intervention: night time ranitidine
Number of subjects: 12
Study 6311692 — intervention group
Group type: EXPERIMENTAL
Intervention: twice daily cimetidine
Number of subjects: 12
Study 6311692 — intervention group
Group type: EXPERIMENTAL
Intervention: night time cimetidine
Number of subjects: 12
Study 30582753 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 μg of sublingual misoprostol
Number of subjects: 87
Study 30582753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 28673310 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced content feedback intervention
Number of subjects: 0
Study 28673310 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced follow-on support feedback intervention
Number of subjects: 0
Study 28673310 — intervention group
Group type: COMPARATOR
Intervention: Current practice (control group)
Number of subjects: 0
Study 27237936 — intervention group
Group type: EXPERIMENTAL
Intervention: HTS training with electrical stimulation
Number of subjects: 16
Study 27237936 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTR)
Number of subjects: 16
Study 25222001 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilayer amniotic membrane transplantation (AMT)
Number of subjects: 26
Study 25222001 — intervention group
Group type: COMPARATOR
Intervention: Lamellar corneal transplantation (LCT)
Number of subjects: 26
Study 25222001 — intervention group
Group type: COMPARATOR
Intervention: Lamellar scleral transplantation (LST)
Number of subjects: 26
Study 21971319 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone, 0.5 µg/kg/min during hypothermic cardiopulmonary bypass
Number of subjects: 0
Study 21971319 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study 19651277 — intervention group
Group type: COMPARATOR
Intervention: Sitting position HCVR in patients with tetraplegia
Number of subjects: 19
Study 19651277 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position HCVR in healthy controls
Number of subjects: 19
Study 19651277 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine FVC in patients with tetraplegia
Number of subjects: 19
Study 19651277 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine HCVR in patients with tetraplegia
Number of subjects: 19
Study 19651277 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean supine blood pressure in patients with tetraplegia
Number of subjects: 19
Study 19651277 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean erect blood pressure in patients with tetraplegia
Number of subjects: 19
Study 17469236 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB (3 g/d)
Number of subjects: 16
Study 17469236 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 16
Study 14981122 — intervention group
Group type: EXPERIMENTAL
Intervention: DCMs stored in artificial saliva for 250 days
Number of subjects: 0
Study 14981122 — intervention group
Group type: COMPARATOR
Intervention: DCMs stored in artificial saliva for 24 hours and 90 days
Number of subjects: 0
Study 14981122 — intervention group
Group type: COMPARATOR
Intervention: DCMs stored with proteolytic enzyme inhibitors or mineral oil
Number of subjects: 0
Study 11356653 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal cocaine exposure (PCE)
Number of subjects: 21
Study 11356653 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prenatal cocaine exposure)
Number of subjects: 21
Study 11356653 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups during active sleep
Number of subjects: 21
Study 11356653 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups during quiet sleep
Number of subjects: 21
Study 11356653 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study 9408555 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexedrine
Number of subjects: 10
Study 9408555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8195581 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 8195581 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0
Study 3793849 — intervention group
Group type: COMPARATOR
Intervention: Placebo membrane
Number of subjects: 6
Study 3793849 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg testosterone membrane
Number of subjects: 6
Study 3793849 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg testosterone membrane
Number of subjects: 6
Study 3793849 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg testosterone membrane
Number of subjects: 6
Study 30559106 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/d
Number of subjects: 31
Study 30559106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 27775485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively complex card game (trained group)
Number of subjects: 29
Study 27775485 — intervention group
Group type: COMPARATOR
Intervention: Computerized version of a simple dice-game of chance (control group)
Number of subjects: 29
Study 26100557 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% scFOS
Number of subjects: 0
Study 26100557 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% scFOS
Number of subjects: 0
Study 26100557 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% scFOS
Number of subjects: 0
Study 26100557 — intervention group
Group type: COMPARATOR
Intervention: Control diet (0% scFOS)
Number of subjects: 0
Study 26100557 — intervention group
Group type: EXPERIMENTAL
Intervention: scFOS (various concentrations)
Number of subjects: 0
Study 24952855 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 genotype-guided antiplatelet therapy (clopidogrel for *1/*1 patients, ticagrelor or prasugrel for *2 or *3 allele carriers)
Number of subjects: 2700
Study 24952855 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment with ticagrelor or prasugrel
Number of subjects: 2700
Study 24952855 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 genotype-guided antiplatelet therapy
Number of subjects: 2700
Study 22540993 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist with a long-term protocol
Number of subjects: 64
Study 22540993 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist with a multi-dose protocol
Number of subjects: 64
Study 19481812 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (40 mg in 1 ml)
Number of subjects: 163
Study 19481812 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 163
Study 17539869 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-supplemented breakfast
Number of subjects: 0
Study 17539869 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-supplemented breakfast
Number of subjects: 0
Study 17539869 — intervention group
Group type: COMPARATOR
Intervention: Basic breakfast
Number of subjects: 0
Study 15334625 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg metformin
Number of subjects: 24
Study 15334625 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg metformin
Number of subjects: 24
Study 15334625 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 mg metformin
Number of subjects: 24
Study 15334625 — intervention group
Group type: EXPERIMENTAL
Intervention: 2500 mg metformin
Number of subjects: 24
Study 11489571 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (40 eyes)
Number of subjects: 50
Study 11489571 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound (US) (25 eyes)
Number of subjects: 50
Study 9535416 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 169
Study 9535416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 7632462 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine therapy
Number of subjects: 28
Study 2506217 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms octreotide
Number of subjects: 10
Study 2506217 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms octreotide
Number of subjects: 10
Study 2506217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 793550 — intervention group
Group type: EXPERIMENTAL
Intervention: Pericardium closed with interrupted silk
Number of subjects: 200
Study 793550 — intervention group
Group type: COMPARATOR
Intervention: Pericardium left open
Number of subjects: 200
Study 793550 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study 31586198 — intervention group
Group type: EXPERIMENTAL
Intervention: Common surgical method (1a) with soft palate closure at 3-4 months and hard palate closure at 12 months
Number of subjects: 429
Study 31586198 — intervention group
Group type: EXPERIMENTAL
Intervention: Common surgical method (2a) with soft palate closure at 3-4 months and hard palate closure at 12 months
Number of subjects: 429
Study 31586198 — intervention group
Group type: EXPERIMENTAL
Intervention: Common surgical method (3a) with soft palate closure at 3-4 months and hard palate closure at 12 months
Number of subjects: 429
Study 31586198 — intervention group
Group type: COMPARATOR
Intervention: Delayed hard palate closure (1b)
Number of subjects: 429
Study 31586198 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous closure of both hard and soft palate at 1 year (2c)
Number of subjects: 429
Study 31586198 — intervention group
Group type: COMPARATOR
Intervention: Hard palate closure together with lip closure at 3 months and soft palate closure at 1 year (3d)
Number of subjects: 429
Study 31645286 — intervention group
Group type: EXPERIMENTAL
Intervention: Light general anaesthesia (BIS target 50)
Number of subjects: 6644
Study 31645286 — intervention group
Group type: COMPARATOR
Intervention: Deep general anaesthesia (BIS target 35)
Number of subjects: 6644
Study 28875295 — intervention group
Group type: EXPERIMENTAL
Intervention: SWL
Number of subjects: 582
Study 28875295 — intervention group
Group type: EXPERIMENTAL
Intervention: RIRS
Number of subjects: 582
Study 28875295 — intervention group
Group type: EXPERIMENTAL
Intervention: PCNL
Number of subjects: 582
Study 26062658 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical trauma
Number of subjects: 88
Study 26062658 — intervention group
Group type: EXPERIMENTAL
Intervention: Crime-related trauma
Number of subjects: 88
Study 26062658 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD symptom severity
Number of subjects: 88
Study 23856771 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2336805 (150 mg single dose)
Number of subjects: 0
Study 23856771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21286910 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection suspension arthroplasty according to Epping
Number of subjects: 84
Study 21286910 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapezectomy with interposition of pyrocarbon spacers
Number of subjects: 84
Study 19150702 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-up treatment with antacid, H2-receptor antagonist, and proton pump inhibitor (n=341)
Number of subjects: 664
Study 19150702 — intervention group
Group type: COMPARATOR
Intervention: Step-down treatment with proton pump inhibitor, H2-receptor antagonist, and antacid (n=323)
Number of subjects: 664
Study 19150702 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-up treatment (n=341)
Number of subjects: 664
Study 19150702 — intervention group
Group type: COMPARATOR
Intervention: Step-down treatment (n=323)
Number of subjects: 664
Study 17199535 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP with the periodontal endoscope
Number of subjects: 15
Study 17199535 — intervention group
Group type: COMPARATOR
Intervention: SRP without the periodontal endoscope (control)
Number of subjects: 15
Study 15119993 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg levofloxacin for 5 days
Number of subjects: 123
Study 15119993 — intervention group
Group type: COMPARATOR
Intervention: 500 mg levofloxacin for 10 days
Number of subjects: 123
Study 11802678 — intervention group
Group type: EXPERIMENTAL
Intervention: HR feedback training (FB+)
Number of subjects: 25
Study 11802678 — intervention group
Group type: COMPARATOR
Intervention: Control group (FB-)
Number of subjects: 25
Study 9566995 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-fat rice bran (84 g/d)
Number of subjects: 44
Study 9566995 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat bran (84 g/d)
Number of subjects: 44
Study 9566995 — intervention group
Group type: COMPARATOR
Intervention: Rice starch placebo
Number of subjects: 44
Study 8281622 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron
Number of subjects: 66
Study 8281622 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 66
Study 1698846 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro reactivity and sensitivity of basophils to antigen for histamine release
Number of subjects: 22
Study 1698846 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of basophil, antigen, histamine, and codeine skin sensitivity and reactivity
Number of subjects: 22
Study 1698846 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigen sensitivity, basophil and mast cell reactivity, and end organ responsiveness to mediators
Number of subjects: 22
Study 1273734 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of oral PGE2 given hourly
Number of subjects: 37
Study 1273734 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubling the dose of oral PGE2 hourly, starting with 0.5 mg and increasing to a maximum of 2.0 mg
Number of subjects: 37
Study 1273734 — intervention group
Group type: COMPARATOR
Intervention: Both regimens of oral PGE2
Number of subjects: 37
Study 31600429 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month structured exercise intervention (n=21)
Number of subjects: 31
Study 31600429 — intervention group
Group type: COMPARATOR
Intervention: 3-month waitlist control (n=10)
Number of subjects: 31
Study 31326270 — intervention group
Group type: EXPERIMENTAL
Intervention: FRESH score
Number of subjects: 107
Study 28188965 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate (ZS) 220-mg capsules (50 mg elemental zinc) from the 16th day of the menstrual cycle to the second day of the next cycle
Number of subjects: 142
Study 28188965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 25605632 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback group (n = 29)
Number of subjects: 57
Study 25605632 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 28)
Number of subjects: 57
Study 23212438 — intervention group
Group type: EXPERIMENTAL
Intervention: Active bupropion
Number of subjects: 416
Study 23212438 — intervention group
Group type: COMPARATOR
Intervention: Placebo bupropion
Number of subjects: 416
Study 16796081 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation group program (n=46)
Number of subjects: 81
Study 16796081 — intervention group
Group type: COMPARATOR
Intervention: Regular treatment group (n=35)
Number of subjects: 81